JAMA Network
About The Study: In 2024, 8.3% of U.S. adults—an estimated 21.3 million—reported ever having long COVID (LC), among whom nearly 6 in 10 reported recovery, consistent with RECOVER initiative findings showing similar LC prevalence in 2023 and 2024 and longitudinal Veterans Affairs data demonstrating declining LC prevalence. Yet many adults, particularly those 35 years or older, continue to experience lasting symptoms. With no LC treatment demonstrating clear efficacy, greater investment in understanding biological mechanisms, including immunotypic differences between those who recover and those who do not, may provide insights into pathways of persistence and potential targets for intervention.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
